~~<i id='21ED866A71'><strike id='21ED866A71'><tt id='21ED866A71'><pre id='21ED866A71'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

entertainment

author：leisure time 2025-09-29 13:46:08 - browse：1733

A box of Sudafed PE sinus pressure and pain medicine. -- health coverage from stat — PATRICK T. FALLON/AFP via Getty Images

You would have been forgiven for being surprised on Sept. 12 when a panel of advisers to the Food and Drug Administration concluded that the active ingredient in Sudafed PE and other over-the-counter decongestants is completely ineffective. It was front-page news, birthed myriad explainer stories on the internet, and even inspired a lawsuit against companies that sold the medicine, phenylephrine.

Yet when T.J. Parker, the entrepreneur and pharmacist who sold PillPack to Amazon, saw the news, he tweeted, “Didn’t everyone know this?”

He had a point.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： European regulators recommend Amylyx's ALS drug be rejected

Wikipedia

focus

knowledge

hotspot

focus

hotspot

ISSOUFSANOGO/AFPviaGettyImagesMorethanonein10infantsworldwidearebornpreterm,manywithcomplications:Ne

WSS

How doctors and nurses shape Google's AI

What's changing in Medicare's open enrollment this year?

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

Biden administration sends mixed signals on US soldier who crossed into North Korea

European regulators consider appeal over Amylyx ALS drug

hotspot

entertainment

Wikipedia

DIEP, the 'gold standard' of breast reconstruction, is under threat

European regulators consider appeal over Amylyx ALS drug

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Flagship, Pfizer team up in deal worth up to $7 billion

As demand for Covid shots wanes, Moderna seeks its next success

A look at other Americans who have crossed into North Korea over the years

Apple is now the first public company to be valued at $3 trillion

A strong 6.5

Psychedelics group wrestles with new pharma identity

STAT Readout: Today's biotech news includes Sana and Amylyx

focus

Medicare to cover more brain scans related to Alzheimer’s drugs

Medicare to cover more brain scans related to Alzheimer’s drugs

Manchin plays down potential 3rd

FDA seeking to stop procedures at two unregulated stem cell clinics

More hospitals are billing patients as online messages surge

How clinical AI models' predictive power can degrade over time

knowledge

hotspot

focus

hotspot